James N. George , MD



George Lynn Cross Research Professor


Phone: (405) 271-4222, ext. 48390
Office: The University of Oklahoma Health Sciences Center
801 Northeast 13th Street, Room 335
Post Office Box 26901
Oklahoma City, Oklahoma 73126-0901
Email: James-George@ouhsc.edu


B.A., M.D., The Ohio State University
Post-Doctoral Training, Vanderbilt University, Walter Reed Army
   Institute of Research, University of Rochester


George Lynn Cross Professor, Department of Medicine, 2005-present.
Professor, Department of Medicine, University of Oklahoma Health
   Sciences Center, 1990-present.
Assistant, Associate, Professor, Department of Medicine, University
   of Texas Health Science Center at San Antonio, 1970-1990.



American Society of Hematology, President, 2005; Director, Clinical Research Training Institute, 2003, 2004; Editor, ASH Self-Assessment Program, 1st Edition, 2002; Mentor Award Study Section Chair, 2006-2007.

National Heart Lung Blood Institute Strategic Planning Working Group, 2006.


  • George JN, Vesely SK:  Immune thrombocytopenic purpura - Let the treatment fit the patient.  New Eng J Med 349: 903-905, 2003
  • Colman RW, Marder VJ, Clowes A, George JN, Goldhaber SZ (editors): Hemostasis and Thrombosis. Basic Principles and Clinical Practice, Lippincott Williams and Wilkins, Philadelphia, 5th ed, 2006
  • George JN:  Thrombotic thrombocytopenic purpura.  New Eng J Med 354: 1927-1935, 2006
  • George JN:  Management of refractory immune thrombocytopenic purpura.  J Thromb Haemost 4: 1664-1672, 2006
  • Bussel JB, Kuter DL, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen C-F, Nichol JL:  AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.  New Eng J Med 355: 1672-1681, 2006
  • Nurden AT, Phillips DR, George JN:  Platelet membrane glycoproteins: historical perspectives.  J Thromb Hemost  4: 3-9, 2006


  • Epidemiology
  • Clinical Course
  • Long-term outcomes of platelet disorders


  • The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry.  This is an inception cohort of all patients with clinically diagnosed TTP or HUS in Oklahoma, excluding the Tulsa region, since January 1, 1999.  The Registry is an ongoing study of the etiology, diagnosis, management, and long-term outcomes of patients with TTP or HUS, excluding only children with typical, Shiga toxin-induced HUS.  Current Registry projects include the association of autoimmune etiologies of TTP with other autoimmune disorders, such as systemic lupus erythematosis and long-term neurocognitive outcomes following recovery from acute episodes of TTP.
  • Immune thrombocytopenic purpura (ITP).  Multiple studies are being conducted to evaluate the safety and effectiveness of new agents to treat patients with ITP.
  • Drug-induced thrombocytopenia.  A continuing Registry has been initiated to document the levels of evidence in all published case reports describing patients with drug-induced thrombocytopenia, to create a comprehensive database on our webite (http://moon.ouhsc.edu/jgeorge) that lists all drugs that have been associated with thrombocytopenia and the level of evidence regarding causality.  Continuing research is comparing our data to data mining of the FDA Adverse Event Reporting System (MedWatch) database, and data on laboratory detection of drug-dependent anti-platelet antibodies.



NIH 1U01HL72283, “Oklahoma-UT Southwestern Hemostasis Consortium”, a Core Clinical Center of the NHLBI Transfusion Medicine/Hemostasis Clinical Research Network.  October 1, 2002-September 30, 2012, James N. George, M.D., principal investigator.